Solid Biosciences (SLDB) Share-based Compensation (2017 - 2026)

Solid Biosciences has disclosed Share-based Compensation across 10 years of filings, most recently posting $5.2 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $5.2 million, up 54.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.7 million (up 52.87% YoY), and the FY2025 annual result was $16.9 million, up 60.79% from the prior year.
• Share-based Compensation came in at $5.2 million for Q1 2026 at Solid Biosciences, down from $6.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.5 million in Q4 2025 to a low of $1.5 million in Q3 2022.
• The 5-year median for Share-based Compensation is $2.1 million (2023), against an average of $2.8 million.
• Across the five-year window, Share-based Compensation plunged 55.39% in 2022 and jumped 107.39% in 2025, its largest moves.
• Solid Biosciences' Share-based Compensation stood at $1.6 million in 2022, then increased by 22.12% to $1.9 million in 2023, then jumped by 97.16% to $3.8 million in 2024, then jumped by 70.11% to $6.5 million in 2025, then dropped by 20.74% to $5.2 million in 2026.
• The last three Share-based Compensation figures came in at $5.2 million (Q1 2026), $6.5 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.